
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies is facing a challenging capital environment with a recent $2.0M registered direct financing, leading the financial analyst to lower the stock rating from Buy to Hold. However, the company's partnership with AbbVie for their dermal filler and the potential for positive data or regulatory advances for their own regenerative candidates provide potential catalysts for improved market outlook and cashflow. Despite de minimis revenues and a reduction in operating expenses, CollPlant holds a solid cash balance of $8.5M as of September 30, 2025.
Bears say
CollPlant Biotechnologies is highly reliant on its partnership with AbbVie to develop and commercialize its proprietary rhCollagen product, posing a significant risk if the collaboration is unsuccessful or does not result in high demand for its products. The company also faces significant risks in clinical and regulatory processes, competition in the market, and potential legal and intellectual property issues, which could hinder its growth and profitability. Additionally, decreasing revenues and a tight cost base signal potential financial difficulties in the near-term.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares